Trial Profile
GLUCOSE METABOLISM AND INFLAMMATORY PARAMETERS UNDER IGF-I TREATMENT IN CYSTIC FIBROSIS METABOLISMO GLUCIDICO E PARAMETRI INFIAMMATORI DURANTE TRATTAMENTO CON RHIGF-I NELLA FIBROSI CISTICA
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2014
Price :
$35
*
At a glance
- Drugs Mecasermin (Primary)
- Indications Diabetes mellitus; Glucose intolerance
- Focus Pharmacodynamics
- Sponsors Ipsen
- 03 Mar 2014 New trial record